beta

CPRX

Catalyst Pharmaceuticals Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

Market Cap: 1.87 Billion

Primary Exchange: NASDAQ

Website: https://catalystpharma.com/

Shares Outstanding: 118 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.2982394160599813

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 997 trading days

From: 2015-07-22 To: 2019-04-24

Lowest Point:

Catalyst sues FDA over approval of Firdapse competitor in LEMS

via: SeekingAlpha at 2019-06-12 05:22:46:000

Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM… read more...

Catalyst sues FDA over approval of Firdapse competitor in LEMS

via: SeekingAlpha at 2019-06-12 05:22:46:000

Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud